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Abstract
Hemophilia A is caused by mutations in the gene encoding factor VIII (F8) and is an important target for gene therapy. The F8 gene contains 26
exons spread over ∼186 kb and no work using the intact genomic locus has been carried out. We have constructed a 250-kb BAC carrying all 26
exons, the introns, andmore than 40 kb of upstream and 20 kb of downstreamDNA. This F8 BACwas further retrofitted with either the oriP/EBNA-1
elements from Epstein–Barr virus, which allow episomal maintenance in mammalian cells, or alphoid DNA, which allows human artificial
chromosome formation in some human cell lines. Lipofection of the oriP/EBNA-1-containing version into mouse Hepa1-6 cells resulted in
expression of F8mRNA spanning theF8 gene. The N300-kb BAC carrying alphoid DNAwas successfully delivered to 293A andHT1080 cells using
bacterial delivery, resulting in greater than endogenous levels of F8 mRNA expression.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hemophilia A; Factor VIII; F8; Gene therapy; Bacterial artificial chromosome; BAC; Bacterial delivery; oriP/EBNA-1; alphoid DNAHemophilia A is a bleeding disorder caused by deficiency in
the activity of coagulation factor VIII (FVIII). There are different
degrees of severity, depending on the levels of the protein in the
blood, but in general all are characterized by spontaneous and
frequent bleeds. It is an X-linked disorder affecting approxi-
mately 1 in 5000 male births and is currently treated by infusion
of plasma-derived or recombinant clotting factor, which is very
expensive and temporary. This disease is an attractive target for
gene therapy because it is entirely due to mutations in one gene
and low levels of expression should have a large clinical benefit
(reviewed in [1]).
Current approaches to gene therapy generally rely on the
expression of a cDNA from viral vectors such as adenovirus or a
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doi:10.1016/j.ygeno.2007.07.005generally have limited tissue specificity or control elements and
they are susceptible to being switched off by neighboring chro-
matin. Furthermore, viral packaging limits the length of the
DNA fragment that can be delivered. For hemophilia A, even the
7-kb open reading frame [3] is too large for many viral vectors
and shortened versions lacking the nonessential B domain are
commonly used. The entire F8 gene spans more than 180 kb [4]
and has never been used for expression of FVIII.
Improved gene therapy vectors should be able to drive
physiological, controlled levels of the transgene and give ex-
pression for long periods of time. The use of large DNA frag-
ments to introduce not only the gene itself, with exons and
introns, but also all the regulatory elements, has been very
successful in transgenic mice in giving full levels of physiolo-
gically controlled expression for a number of hard-to-express
genes such as huntingtin [5] and CFTR [6]. The use of genomic
fragments could be similarly useful in gene therapy applications
but almost all work has been carried out with cDNA-based
constructs. In addition, systems that allow the DNA to replicate
and segregate alongside the endogenous chromosomes should
allow long-term maintenance even in dividing cells, without the
Fig. 1. Recombination of two overlapping BACs to make the F8 BAC. (A) Map of the F8 gene showing the exons spread over ∼180 kb. BAC RP11-524G17 was
found to have an∼70-kb deletion (marked in gray). The sequence for BAC RP11-273L24 is also given in GenBank. BAC1 and BAC2 were recombined to form the F8
BAC. The NotI and SalI digests of the insert of the F8 BAC are shown at the bottom. (B) Map of the recombineering vector that carries two regions of homology to
BAC1 (HomA and HomB), the F1 BAC origin, and chloramphenicol and gentamicin resistance genes, all cloned into pBluescript. Digestion with NotI releases the
fragment that is used to recombine with BAC1. (C) Diagram showing how recombination takes place between BAC1 and the recombineering vector, resulting in
BAC1subcloned. Primers used in PCR to identify colonies containing correctly recombined BACs are labeled 1 and 2. (D) Map of BAC1subcloned showing the SalI
and PI-PspI sites. (E) Pulsed-field gel showing BAC1subcloned digested with SalI. (F) Diagram showing how recombination takes place between BAC1subcloned
digested with PI-PspI and BAC2. Homologous recombination takes place in HomB and the chloramphenicol resistance gene. Primers used in PCR to identify colonies
containing correctly recombined BACs are labeled 1 and 3.
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612 S. Pérez-Luz et al. / Genomics 90 (2007) 610–619dangers of insertional mutagenesis [7]. Episomal replication and
segregation can be achieved by linking genomic fragments to
viral elements or a mammalian centromere.
Epstein–Barr virus has a latent phase during which it is
maintained in human lymphocytes for life, in an asymptomatic
manner. The only elements needed for episomal maintenance of
a plasmid are the latent origin of replication (oriP) and the
protein EBNA-1 [8]. Constructs carrying oriP and the EBNA-1
gene can express therapeutic genes for long periods of time both
in vitro and in vivo (reviewed in [7]). In general this has involved
the use of minigenes but in some cases large genomic fragments
have been used and the genes have been expressed, including
tumor necrosis factor [9], β-globin [10,11], CFTR [12], HPRT
[13], α1-antitrypsin [14], LDLR [15], and CDKN2A/CDKN2B
[16].
Human artificial chromosomes (HACs) which replicate and
segregate faithfully alongside the endogenous chromosomes,
can be formed de novo after transfection of DNA constructs
containing greater than about 50 kb of centromeric alphoid
DNA (reviewed in [17]). A number of intact genes have been
incorporated into such HACs and they have been well
expressed, including HPRT [18,19], guanosine triphosphate
cyclohydrolase I [20], and β-globin [21].
A major challenge of functional studies using large genomic
constructs is achieving efficient delivery of intact DNA to
mammalian cells. We have previously shown that a 150-kb
bacterial artificial chromosome (BAC) could be efficiently
delivered into cells with Lipofectamine 2000 and that more than
half the stable transformed cell lines contained the delivered
BAC intact [22,23]. However, this requires purification of
supercoiled BAC DNA, which becomes increasingly difficult
with larger BACs. More efficient delivery of intact BAC DNA
has been achieved using a herpes simplex virus type 1 packaging
system but this packages efficiently only up to about 170 kb [24],
well below the size of the F8 gene.
Direct delivery from the bacterial host to the mammalian cells
obviates the need to purify the BAC DNA. Several laboratories
have demonstrated that attenuated intracellular bacteria, such as
Shigella, invasive Escherichia coli, Salmonella, and Listeria,
that have been engineered to lyse after cell invasion can transfer
functional genes to a very broad range of mammalian cells [25].
We have shown that invasive E. coli, which undergo lysis upon
entry into mammalian cells because of impaired cell wall
synthesis due to diaminopimelate (dap) auxotrophy, can
efficiently deliver plasmid DNA to mammalian cells [26].
Plasmid pGB2Ωinv-hly, containing the inv gene from Yersinia
pseudotuberculosis and the hly locus from Listeria monocyto-Fig. 2. F8, F8OE, and F8alphoid BACs. (A) Map of the F8 BAC, which carries an∼2
and SalI (S) sites are shown along with the sizes of the fragments generated (not und
showing the fragments obtained after digestion with NotI and SalI. (B) Map of F8OE
for convenience, but it is integrated. On the right is a pulsed-field gel showing tw
F8alphoid BAC and pulsed-field gel showing five colonies of the F8 BAC retrofitted
retrofitted BACs all contain the expected 6.3- (vector), 7.5-, 18-, and 20-kb SalI fragm
which gives different vector fragments. The 203-kb fragment is not visible due to parti
arrays (marked by asterisks) range from about 30 to 70 kb in size. In colony 6 the alph
as a control. The alphoid array purified from pBelo7c5 cut with I-PpoI appears larggenes, has been introduced into the dap auxotroph E. coli
BM2710 [27]. The inv gene (encoding invasin) confers to E. coli
the ability to invade nonphagocytic cells provided they express
β1-integrins. The hly gene product, listeriolysin O, is a pore-
forming cytolysin that allows escape of the bacteria, or of its
cytoplasmic content, from the vacuole of entry. Transfer of
functional DNA into a variety of mammalian cell lines occurs
after simple co-incubation with the bacterial vector [27].
Recently, a 200-kb BAC was transferred into HeLa cells using
a dap-DH10B derivative, made invasive by transformation with
pGB2Ωinv, as demonstrated by EGFP expression 48 h after
transfection [28]. We have used the recombination-deficient and
dap auxotroph strain E. coli BM2710 expressing invasin and
listeriolysin O to deliver into HT1080 cells two PACs containing
alphoid DNA of 150 and 200 kb, respectively, which formed
HACs upon cell transfer, and an engineered 160-kb PAC con-
struct containing a large portion of the human CFTR locus [29].
In this paper, we describe the construction of a BAC clone
containing the entire F8 gene and flanking DNA, which should
contain the associated long-range controlling elements, to
achieve full levels of controlled expression. The BAC has
been retrofitted separately with mammalian selectable markers
and either the oriP and EBNA-1 functions from Epstein–Barr
virus or about 70 kb of alphoid DNA. These BACs were
delivered into mouse and human cells using Lipofectamine 2000
or bacterial delivery, respectively, and shown to drive F8 mRNA
expression.
Results
Construction of a BAC carrying the intact F8 gene
The gene encoding FVIII (the F8 gene) is composed of 26
exons spanning about 186 kb [4]. Searching the Ensembl
database (http://www.ensembl.org/index.html) led to the iden-
tification of one BAC, RP11-524G17, which seemed to contain
not only the gene, but also upstream and downstream regions
that would include some associated regulatory elements.
Analysis of this BAC obtained from two different sources,
the Sanger Institute and the CHORI Center, showed that an
∼70-kb region was missing (Fig. 1A). Further searches of the
Human BAC END sequences database (http://www.tigr.org/
tdb/humgen/bac_end_search/bac_end_intro.html) led to the
identification of a number of unsequenced BACs containing
parts of the F8 gene but none containing the entire locus.
As a single BAC containing the entire F8 gene was not
available, one was constructed by recombining two overlapping50-kb insert and chloramphenicol and gentamicin resistance genes. The NotI (N)
erlined for NotI sites, underlined for SalI sites). On the right is a pulsed-field gel
BAC. The second copy of pRetroNeoOE is shown outside the circle of the BAC
o colonies of F8OE BAC and pRetroNeoOE digested with NotI. (C) Map of
with the alphoid array (prior to retrofitting with pNelγ) digested with SalI. The
ents from the F8 BAC. The map shows the BAC after retrofitting with pNELγ,
al degradation of the very large BACDNA in these minipreps. The alphoid DNA
oid array is the same size (70 kb) as in the HPRT-alphoid BAC, which was loaded
er due to overloading of this lane.
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strategy [30] based on the Red system in EL350 bacteria [31],
which allows genomic regions of overlapping BACs to berecombined into a single BAC seamlessly. A number of BACs
identified from the BAC END database were digested withNotI,
run on a pulsed-field gel, and hybridized with the F8 cDNA. This
614 S. Pérez-Luz et al. / Genomics 90 (2007) 610–619allowed the BACs to be mapped with respect to the F8 gene and
identified two BACs that covered the complete gene suitably. By
recombining 2037E7 (BAC1) and R-474J8 (BAC2), the
resulting BAC will have not only the whole F8 gene but also
more than 40 kb upstream and at least about 20 kb downstream,
and thus should contain all the F8 regulatory elements (Fig. 1A).
The strategy for recombining the two overlapping BACs
involved two steps and is shown in Fig. 1. In the first step, a 62.5-
kb region upstream of the F8 gene and into the first intron was
subcloned by homologous recombination from BAC1 into the
recombineering vector (Figs. 1B, 1C, and 1D). To do this, the
recombineering vector was digested with NotI, and the fragment
flanked by the homology regions (HomA and HomB) was
electroporated into EL350 bacteria containing BAC1 and
induced for the Red recombination genes. In this step, re-
combination should take place at the two homology regions
(HomA and HomB) (Fig. 1C). Gentamicin-resistant and
ampicillin-sensitive colonies were further analyzed by PCR
using a pair of primers located on either side of the HomB region
(indicated as 1 and 2 in Fig. 1C). Three colonies with correctly
modified BACs (called BAC1subcloned) were identified (Figs.
1D and 1E). All three contained the same four expected SalI
fragments of 7.5, 18, 20, and 24 kb (17 kb of insert and 7 kb of
vector) (Figs. 1D and 1E).
The next step was to recombine BAC1subcloned and BAC2
together (Fig. 1F). BAC1subcloned was digested with PI-PspI,
a rare-cutting endonuclease, and electroporated into electro-
competent and Red-induced EL350 bacteria containing BAC2.
Recombination took place within HomB (which is at one end
of BAC2) and in the chloramphenicol resistance gene.
Gentamicin-resistant clones were screened with a PCR assay
(primers labeled 1 and 3 in Fig. 1F) and 5 positive colonies (of
33 screened) were further analyzed by NotI digestion (Fig. 2A).
All were found to contain the same expected fragments of
∼53.6 (43.6 kb of insert plus 10 kb of vector), 73.4, and 130 kb
(Fig. 2A). SalI restriction generated the expected fragments of
6.3 (vector), 7.5, 18, 20, and 203 kb (Fig. 2A). This is called
the F8 BAC and contains the entire F8 gene and flanking
regions.
Retrofitting the F8 BAC for episomal maintenance
The F8 BAC was then retrofitted with a mammalian select-
able marker and with different elements that would allow the
BAC to replicate and segregate in mammalian cells. The oriP/
EBNA-1 elements from Epstein–Barr virus and a G418
resistance cassette for selection in mammalian cells were intro-
duced with the plasmid pRetroNeoOE [22]. Plasmid pRetro-
NeoOE integrates onto BACs at the loxP site by cre/loxP
recombination using Cre recombinase, which can be induced in
the EL350 bacteria. All the resulting F8OE BAC clones
analyzed showed the expected fragments of 61, 73.4, and
130 kb after NotI digestion, showing that no rearrangements
have taken place in the insert of the BAC during recombination
(Fig. 2B). The 61-kb fragment is predicted to result from the
53.6-kb fragment of F8 BAC into which the pRetroNeoOE
vector has integrated at the loxP site (Fig. 2B). In addition, a 9.7-kb fragment was observed, which is the same size as the
pRetroNeoOE vector (Fig. 2B). This can be explained by the
insertion of a second copy of pRetroNeoOE at the loxP site
(Fig. 2B).
A 70-kb region of alphoid DNAwas separately introduced to
allowHAC formation from the BAC. The 70 kb of alphoid DNA
was introduced onto the F8 BAC using Red homologous re-
combination and the universal BAC retrofitting vector pBelo7c5
[32] (Fig. 2C). The 70-kb alphoid DNA plus a spectinomycin
resistance gene inserts into the chloramphenicol resistance gene
on a BAC so that it ends up flanked by the two halves of the
chloramphenicol resistance gene (Fig. 2C). Five clones were
identified with the correct recombination event, but pulsed-field
gel analysis revealed that some contained rearrangements of the
alphoid DNA (Fig. 2C). Only colony 6 contained the intact array
in addition to the expected F8 SalI fragments of 6.3, 7.5, 18, 20,
and 203 kb (Fig. 2C). The alphoid array on this clone is the same
size as that on the HPRTalphoid BAC (Fig. 2C), which has been
shown to form HACs efficiently in HT1080 human cells [32]. A
mammalian G418 resistance selectable marker and EGFP
reporter gene were further introduced into this BAC using the
plasmid pNELγ [33], which integrates into the loxP sites by cre/
loxP recombination (Fig. 2C). This gave the final F8alphoid
BAC (Fig. 2C).
F8 mRNA expression in mouse cells
As the main synthesis of FVIII occurs in the liver, a mouse
liver cell line was used to test for F8 mRNA expression from the
BAC. Purified DNA of the F8 BAC retrofitted with oriP/
EBNA-1 (F8OE BAC) was transfected into mouse Hepa1-6
cells using Lipofectamine 2000 and stable transformants were
selected with G418. Eight stable cell lines were expanded and
analyzed by PCR and RT-PCR to determine whether they
contained and/or expressed human F8. PCR analysis for human
F8 exons 1, 6, and 26 showed that three of the eight cell lines
containing F8OE BAC (B, D, and 1.2) contained all three exons
(Fig. 3A).
Several of the cell lines were analyzed for mRNA expression
using assays spanning exons 1–8 (Fig. 3B), exons 15–19 (Fig.
3C), and exons 18–26 (Fig. 3D). For each of these assays, a
single pair of primers was used to amplify both human and
mouse F8 cDNA equally. The RT-PCR product was then
digested with enzymes specific for either mouse or human
product and run on agarose gels to visualize the amount of each
product. Cell line D did not express exons 1–8 (exons 15–19 and
18–26 not analyzed), cell line 1.2 expressed exons 1–8 and 15–
19 but not detectably exons 18–26, suggesting that there are
deletions or rearrangements in these cell lines. Cell line H, which
was found not to contain exons 6 and 26, did express exons
15–19, again suggesting deletion/rearrangement of the BAC. In
contrast, cell line B expressed at least from exons 1–8 (Fig. 3B),
exons 15–19 (Fig. 3C), and exons 18–26 (Fig. 3D). It thus
probably expresses full-length F8 mRNA and the level of ex-
pression is higher than the endogenous mouse expression as
there is more human-specific than mouse-specific digestion of
the RT-PCR products.
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Expression from the F8alphoid BAC was assessed in
HT1080 and 293A human cell lines. The BAC should contain
all the regulatory elements needed for FVIII expression, but the
cells into which it is introduced also have to contain the
machinery necessary to do so. The F8 gene is expressed mainly
in the liver, but it is also produced in many other cell types [34].
293A cells are derived from kidney and F8 mRNA has been
detected in this tissue; however, it was not known whether
HT1080 cells express F8.
Due to the very large size of the F8alphoid BAC (N300 kb) it
was very difficult to prepare even microgram amounts of
unbroken supercoiled DNA for delivery by lipofection. Instead,
transfection was carried out by bacterial delivery using E. coli
BM4573 [29]. This is a dap-auxotrophic strain expressing the
inv and hly genes to allow DNA delivery to mammalian cellswithout the need to isolate the DNA from the bacterial vector
prior to transfection.
One way to distinguish between the endogenous expression
from the cell lines and the F8 mRNA from the BAC (both
human) is to use natural single-nucleotide polymorphisms
(SNPs). One validated SNP in the 3′ UTR region, that could
form a BsmAI restriction site depending on the base present, was
found in the Ensembl database. The BAC was found to contain
the BsmAI sites, while the cell lines analyzed contained the other
version of the SNP (Fig. 4A). PCR across this SNP followed by
the diagnostic digestion with BsmAI showed that the four
HT1080 cell lines generated all contained the F8 gene from the
BAC (Fig. 4B). In addition, it can be seen that the BAC is
probably present at low copy number per cell (only a proportion
of the PCR product digests with BsmAI) although it is possible
that there is partial digestion of the PCR product.
To detect F8 mRNA using the SNP, a nested PCR was used.
The PCR assay and digestion used to distinguish between the
DNAversions could amplify both RNA and DNA, as it does not
go across any intron. To avoid any DNA-derived product, a new
primer located in exon 25 was designed. In a first PCR, this
primer was used in combination with the reverse primer de-
signed to amplify the DNA, to give a 1.8-kb PCR product that
was hardly seen in a gel but is free of DNA-derived products, as
it crosses an intron. This PCR product was then reamplified
using the DNA primers.
After nested PCR and BsmAI digestion, most of the 293A cell
lines (7/12) and all the HT1080 lines (4/4) were found to express
F8 mRNA from the BAC (Fig. 4C). The HT1080 clones
expressed more F8 from the BAC than endogenous F8, as the
417-bp fragment is brighter than the 559-bp endogenous PCR
product in all four clones. The 293A clones exhibited different
degrees of expression ranging from none in clones 3.1, 3.3, 3.4,
3.6, and 4.1 to predominantly from the BAC in clone 3.2.
FISH experiments were carried out to determine whether the
F8alphoid BAC DNA had formed HACs in the human cellFig. 3. Presence and expression of BAC-derived F8 in Hepa1-6 cell lines
transfected with the F8OE BAC. (A) PCR analysis of various cell lines for the
neo selectable marker and exons 1, 6, and 26 of the F8 gene. The neo assay is
a positive control for the quality of the template DNA and is positive in all the
lanes containing transfected cell lines. The assays for exons 1, 6, and 26 are
human specific and amplify from HepG2 human cells (the assay for exon 6 did
not amplify in this particular experiment), but not from Hepa1-6 mouse cells.
“neo in B16F10” is a positive control for the neo assay and a negative control for
the other assays. Cell lines B, D, and 1.2 contain all three exons. (B) RT-PCR
analysis spanning exons 1 to 8. The primers used amplify both the mouse and the
human F8 cDNAs equally. The product was then digested with either SacI or
SexAI and separated on a gel to visualize the mouse and human product,
respectively. m, SacI cuts mouse product, 451- and 415-bp fragments. h, SexAI
cuts human product, 485- and 381-bp fragments. (C) RT-PCR analysis spanning
exons 15 to 19. The primers amplify both the mouse and the human F8 cDNAs
equally. The product was then digested with either AvaI or PstI and separated on
a gel to visualize the mouse and human product, respectively. m, AvaI cuts mouse
product, 469- and 262-bp fragments. h, PstI cuts human product, 419- and 315-
bp fragments. (D) RT-PCR analysis spanning exons 18 to 26. The primers
amplify both the mouse and the human F8 cDNA equally. The product was then
digested with SexAI and separated on a gel to visualize the human product. The
undigested material remaining is assumed to be largely mouse product. u, no
digestion. h, SexAI cuts human product, 742- and 329-bp fragments.
Fig. 4. Presence and expression of BAC-derived F8 in 293A and HT1080 cell
lines transfected with F8alphoid BAC. (A) PCR across the SNP in the 3′ UTR
followed by digestion (gel shown on right) shows that it is different in the F8
BAC (digests with BsmAI) compared to the human HepG2, 293A, and HT1080
cell lines (do not digest with BsmAI). (B) PCR across the SNP followed by
digestion with BsmAI (right) shows that the BAC-derived F8 DNA is present in
all four HT1080 clones. (C) A nested RT-PCR assay spanning exon 25 and the
SNP in the 3′ UTR shows that F8 is expressed from the transfected BAC in
many of the 293A cell lines and in all four of the HT1080 cell lines as indicated
by BsmAI digestion of some of the RT-PCR product.
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in clones 1.1, 1.2, 1.3, 1.4, 2.1, 3.2, 3.6, and 4.1. Possible HACs
were also observed in 1.4, while no signal was detected in 3.1,
3.3, and 3.4 (clone 1.5 not analyzed). For the HT1080 cell lines,
1.1 showed no exogenous signal, while 2.1, 3.1, and 4.1 all had
integrations.
Discussion
BACs have become a very powerful tool in functional
genomic experiments as they can harbor big DNA fragments
containing not only all the exons and introns of genes but also all
the cis-acting regulatory elements. The Human Genome Project
has made an incredible number of BACs available, sequenced
and unsequenced, in which almost any part of the human
genome can be found. However, the typical size of a BAC is
between 150 and 200 kb, which means that some genes or loci
are not completely included in a single BAC, as happened for theCFTR gene [30] and the F8 gene (this paper). In these cases, it is
very useful to be able to combine different BACs to get the
region of interest in one single vector, and the development of
homologous recombination strategies to do this has been an
important achievement [30,35,36].
Successful homologous recombination between BAC1sub-
cloned and BAC2 led to five colonies, all carrying apparently
identical versions of the 250-kb F8 BAC, suggesting that no
unwanted rearrangements had occurred. This BAC carries the
entire F8 gene along with more than 40 kb upstream and 20 kb
downstream. This F8 BAC was further retrofitted with
mammalian selectable markers and with the oriP/EBNA-1
elements of Epstein–Barr virus to give F8OE BAC and with
70 kb of alphoid DNA to give the F8alphoid BAC.
The F8OE BAC was transfected into murine hepatoma
Hepa1-6 cells using Lipofectamine 2000. One resulting cell line
expressed at least exons 1 to 8, 15 to 19, and 18 to 26 of the F8
mRNA and there was more human than endogenous mouse F8
mRNA being expressed; however, the copy number of the BAC
DNA was not investigated. One way to show that the oriP/
EBNA-1-containing BAC is being maintained as an unrear-
ranged episome in the mouse cells is to rescue episomal DNA
into E. coli [22,37]. Although such rescue was carried out
routinely with a control 150-kb BAC carrying oriP/EBNA-1,
rescue of the 260-kb F8OE BAC was never achieved. This is
probably due to the very large size of the BAC, making
electroporation into E. coli DH10B cells very inefficient, and so
this method could not be used to analyze the episomes.
The F8alphoid BAC was introduced into the human cell lines
293A and HT1080, this time using bacterial delivery. As the
BAC and the human cell lines both contain the human F8 gene, a
SNP located in the 3′ UTR region that varied between the BAC
and the cell lines was used to show that the BAC DNA had
indeed been introduced and to determine whether the mRNA
was being expressed. Seven of 12 of the 293A cell lines
generated expressed F8 mRNA from the BAC. This was
generally at lower levels than the endogenous 293A expression,
but one cell line had higher BAC expression than endogenous.
All four HT1080 cell lines expressed higher than endogenous
levels of F8 from the BAC. In contrast, the copy number of the
BACDNA appeared low but this could have been an artifact due
to partial digestion of the PCR product.
Alphoid DNA has been shown to form de novo centromeres
and human artificial chromosomes in both HT1080 and 293
cells [21,38], while it is not able to do so in murine cell lines
[39]. FISH analysis was carried out to determine the fate of the
BAC DNA; however, almost all the cell lines contained
integrations of the DNA and convincing HACs were not
observed. In HT1080 cells, this 70-kb array of alphoid DNA
has been found to form HACs in 2/14 (14%) cell lines [32] so
it is not surprising to find none in just 4 cell lines. The
frequency of HAC formation with this array in 293 cells is not
known, but HACs have been found to be unstable in 293 cells
[38]. In addition, the presence of the F8 genomic DNA might
either increase or decrease the frequency of HAC formation as
different genomic regions have been shown to have these effects
[21].
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expression. As the different cell lines into which the BACs were
introduced all expressed endogenous FVIII, it would be very
difficult to detect an increase in FVIII function. One would not
expect expression of FVIII from the BAC in cell lines that do not
express endogenous FVIII as they may not contain the necessary
transcription factors. A demonstration of functional FVIII ex-
pression from the BACs therefore awaits the use of cell lines or
mice carrying mutations in the F8 gene.
We have constructed a 250-kb BAC carrying the intact F8
gene and shown that it can drive greater than endogenous levels
of mRNA expression in mouse and human cells in tissue culture.
This BAC is the first characterized genomic clone carrying the
intact F8 gene and could be very useful for identifying the long-
range elements that control full levels of position-independent
and controlled expression of the F8 gene. In addition, the BAC
could potentially be used for therapeutic expression of FVIII.
Materials and methods
BACs and cell lines used
BAC RP11-524G17 was obtained from the Wellcome Trust Sanger
Institute (http://www.sanger.ac.uk/) and the Children's Hospital Oakland
Research Institute (CHORI) BACPAC Resources Center (http://bacpac.chori.
org/). BAC R-474J8 is from the human BAC library RPCI-11 and BAC
2037E7 is from the Caltech human BAC library D1. These were obtained from
the CHORI center.
Mouse hepatoma Hepa1-6 (ATCC No. CRL-1830) and human hepatocel-
lular carcinoma HepG2 (ATCC No. HB-8065) cell lines were obtained from the
American Type Culture Collection. Human fibrosarcoma cell line HT1080 was
obtained from Howard Cooke (Edinburgh). Human 293A cells (Invitrogen) are a
derivative of human kidney 293 cells that have a flattened morphology making
them easy to culture. All cell lines were grown in DMEM (Invitrogen)
supplemented with 10% bFCS (Invitrogen) at 37 °C and 5% CO2.
Purification of BAC DNA and pulsed-field gel electrophoresis
Small amounts of BAC DNA were prepared from 5-ml saturated cultures
using a standard alkali miniprep protocol [40]. For BACs larger than 250 kb in
size, DNA was prepared in agarose plugs [41]. Larger amounts of BAC DNA
(for analysis, subcloning, or transfection) were prepared from 500-ml cultures
using the EndoFree Plasmid Maxi Kits (Qiagen) following the manufacturer's
protocol for low-copy plasmids with the modifications for removing
endotoxins. BAC DNAwas analyzed by restriction enzyme digestion followed
by separation on pulsed-field gels run on a CHEF DRII or DRIII apparatus
(Bio-Rad). The gels were made of 1% agarose and run in 0.5× TBE at 14 °C
and 5.9 V/cm.
Construction of the recombineering vector
The recombineering vector was made from the subcloning vectors pBlS1,
pBlS2Belo, and pBlS3CmGm described by Kotzamanis and colleagues [30].
New homing endonuclease sites (PI-PspI) were cloned into pBlS1 and
pBlS2Belo next to the I-PpoI sites using pairs of complementary primers: for
pBlS1, 5′-GGTAGCCAAAATCCTGGCAAACAGCTATTATGGGTAT-
TATGGGTCTCGAGAGACGAGCT-3′ and 5′-CGTCTCTCGAGACCCA-
TAATACCCATAATAGCTGTTTGCCAGGATTTTGGCTACCTTAA-3′, and
for pBlS2Belo, 5′-GGTAGCCAAAATCCTGGCAAACAGCTATTATGGG-
TATTATGGGTATCGATTCCACCGC-3′ and 5′-GGTGGAATCGATACCCA-
TAATACCCATAATAGCTGTTTGCCAGGATTTTGGCTACCTTAA-3′.
Homology region HomB was amplified from BAC R-474J8 by PCR using
primers HomBFw, 5′-CTCGAGCCGAGAAGCTGGTTTGTCTC-3′, andHomBRv, 5′-CCGCGGACCTTCACACCCCTTCACAG-3′ (position 34256–
35302 of BAC RP11-524G17), and cloned into SacII/XhoI-cut pBlS2Belo to
give pBlS2BeloHomB using the restriction sites present in the PCR primers
(underlined in the sequences given). PCR to amplify both homology regions was
carried out with Platinum Pfx DNA polymerase (Invitrogen) to minimize
introduction of mutations.
The 2.5-kb BamHI/XhoI fragment from pBlS3CmGmwas cloned into pBlS1
digested with BamHI/SalI giving pBlS13CmGm. Homology region HomAwas
amplified from BAC 2037E7 using primers HomAFw, 5′-GTCGACCTTCCC-
CACTGTGTGACCTT-3′, and HomARv, 5′-GGATCCGCCCAGAGAAAGA-
CAACTGC-3′ (position 23689–24834 of BAC RP11-273L24), and cloned into
XhoI/SacI-cut pBlS13CmGm to give pBlS13CmGmHomA using the restriction
sites present in the PCR primers (underlined in the sequences given). Finally,
pBlS2BeloHomB and pBlS13CmGmHomAwere combined together by cloning
the 5.6-kb SalI/SacI fragment from pBlS2BeloHomB into XhoI/SacI-cut
pBlS13CmGmHomA, giving pBlS13CmGmHomA2BeloHomB (referred to as
the recombineering vector in this article).
Electrocompetent cells and Red system induction
Recombination of the two BACs was carried out using the Red homologous
recombination system in EL350 bacteria [31], which carry the recombination
genes under an inducible promoter, following the procedures described
elsewhere [30].
Construction of a BAC carrying the intact F8 gene
For subcloning BAC1, the NotI fragment containing the homology regions
from the recombineering vector was purified using the QIAquick gel extraction
kit (Qiagen), and 50 ng of this DNA was electroporated into BAC1-EL350
bacteria. For linking BAC1subcloned and BAC2, about 2 μg of BAC1subcloned
digested with PI-PspI (not purified) was electroporated into BAC2-EL350
bacteria.
For all recombination events, PCR assays were designed to accelerate the
screening. The following primers were used: ChpB2Fw (5′-TGCTGTACAAT-
GATTCCCCA-3′) (primer 1, Fig. 1C) and Belo2658 (primer 2, Fig. 1C) [30] for
subcloning BAC1, ChpB2Fw (primer 1, Fig. 1F) and ChpB2Rv (5′-AACAG-
GAACCACAGGGAATG-3′) (primer 3, Fig. 1F) for linking the two BACs, and
Belo2658 andSpec1 [32] for introducing the alphoidDNAarray into the F8BAC.
Retrofitting the F8 BAC with pRetroNeoOE, pBelo7c5, and pNelγ
To introduce alphoid DNA into the F8 BAC, about 10 μg of pBelo7c5 [32]
was digestedwith I-PpoI, ethanol precipitated overnight, and then resuspended in
a final volume of 10 μl of 10 mM Tris. Two microliters was electroporated into
induced and electrocompetent EL350 bacteria containing the F8 BAC.
Chloramphenicol-sensitive colonies (SpRGmRCmS) were further checked by
PCR [32]. Seven of the 42 colonies obtained were CmS and positive for the PCR
assay.
EL350 bacteria carrying the F8 BAC or the F8alphoid BAC were made
electrocompetent without induction of the red genes and 100 ng of pRetroNeoOE
[22] or pNelγ [33], respectively, was electroporated into them. Cre-mediated
recombination was induced with 0.1% arabinose (Sigma).
Transfection of Hepa1-6
Transfections were carried out with Lipofectamine 2000 (Invitrogen) as
previously described [22]. The next day, 1/5 or 1/10 of the cells were seeded onto
10-cm tissue culture plates and 300 μg/ml G418 was added 24 h later.
Bacterial delivery into human cell lines
Bacterial delivery was carried out with the dap auxotroph strain E. coli
BM4573 [29], a BM2710 derivative [27]. The BACs were introduced into the
bacterial vector by electroporation and delivered using the protocol described
elsewhere [28]. Cells (4×105) were seeded in six-well plates the day before the
bacterial delivery. Bacteria were grown overnight at 30 °C in brain heart infusion
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bacteria were pelleted by centrifugation and resuspended in DMEM containing
0.5 mM dap to the original culture volume. Bacteria were added to cells to obtain
a multiplicity of infection of 10, 20, or 40. For 293A cells, 20 μM chloroquine
(Sigma) was added to increase the efficiency of delivery. After incubation at
37 °C in 5% CO2 for 2 h, cells were washed to remove nonadherent bacteria, and
fresh medium containing 20 μg/ml gentamicin was added. The next day, 1/4 or
1/5 of the cells were seeded onto 10-cm tissue culture plates and appropriate
selection was added 24 h later.
PCR from cells
DNA was extracted directly from cell lines using the following protocol.
From a six-well plate, cells were trypsinized and recovered in 1.5 ml of
medium. After centrifugation at 1000 rpm for 4 min, the pellet was frozen and
stored at −80 °C for at least overnight. Before the PCR was prepared, the
pellet was resuspended in 200 μl of 2× PCR buffer containing 20 μg of
proteinase K and incubated at 50 °C for 1 h and then at 95 °C for 12 min to
inactivate the proteinase K. Five microliters of this DNA solution was used in
a 50-μl PCR.
The following primers were used to detect DNA from the BAC: exon 1,
F8Ex1F (5′-GGCTGCTTCCCACTGATAAAAAG-3′) and F8Ex1R (5′-TCA-
CAACCATCCTAACCCGATG-3′); exon 6, F8Ex6F (5′-TTTGAGAGGATAA-
GTGCTGTGTGC-3′) and F8Ex6R (5′-CAGAACTCTGGTGCTGAATTTGG-
3′); exon 26, F8Ex26F (5′-GGACTACTGGAAACAACTAGAAGTG-3′) and
F8Ex26R (5′-GGATTTAGCACAAAGGTAGAAGG-3′).
The region flanking the SNP in the 3′ UTR was amplified using the primers
F83′UTRF (5′-TCCAGTCTGCCATATCACCA-3′) and F83′UTRR (5′-
GTCAATGGGAAAAGAATGCC-3′) to give a 559-bp PCR product. To
differentiate the two versions of the SNP, 9 μl of the PCR product was digested
in a 12-μl reaction with the enzyme BsmAI (New England Biolabs). This gives
two bands of 417 and 142 bp in the case of the F8 BAC.
RT-PCR
Total RNA was prepared from six-well plates using the RNeasy Mini Kit
(Qiagen) according to the manufacturer's protocol, with the additional on-
column DNase digestion. cDNA was prepared from 2 μg of total RNA using
SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer's
protocol, and amplification was performed in a 25-μl PCR.
The primers used were sEx1Fw (5′-TCTTTTCCATTCAACACCTC-3′) and
sEx8Rv (5′-TGACATAAGCTTCCATGCCA-3′) for exons 1 to 8, giving an 866-
bp product; F815Fw (5′-CCATATATAAGAGCAGAAGTTG-3′) and F819Rv
(5′-TGCTCGCCAATAAGGCATTC-3′) for exons 15 to 19, giving a 730-bp
PCR product; and F818Fw (5′-CATTTCAGTGGACATGTGTT-3′) and F826Rv
(5′-GAAGGAGTCTTGATTTCCCT-3′) for exons 18 to 26, giving 1071-
(human) and 1031-bp (mouse) products.
As all pairs of primers amplify both human and mouse RNA, specific
digestions were used to differentiate them. For exons 1 to 8, SexAI cuts human
product (485- and 381-bp fragments) and SacI cuts mouse (415- and 451-bp
fragments). For exons 15 to 19, PstI cuts human product (419- and 315-bp
fragments) and AvaI cuts mouse (469- and 262-bp fragments). For exons 18 to
26, SexAI cuts human product (742- and 329-bp fragments).
For mRNA expression of the BAC in the human cell lines a nested PCR
assay across the SNP in the 3′ UTR was used. Primers SNPRNAFw (5′-
TTTTCAGAATGGCAAAGTAAAGG-3′) and F83′UTRR (5′-GTCAATGG-
GAAAAGAATGCC-3′) were used in the first round to give a 1.8-kb fragment
spanning the last intron. One to two microliters of PCR product was then used as
template for the second PCR using primers F83′UTRF and F83′UTRR to obtain
the 559-bp fragment, which was then digested with BsmAI to distinguish the
endogenous (not cut) from the F8 BAC (cuts with BsmAI to give two bands of
417 and 142 bp).
FISH
FISH analysis was carried out as described previously [32]. The probes used
were PAC7c5 [42] (alphoid DNA) labeled with biotin and the F8BAC labeledwith digoxigenin. Signal detection was carried out using reagents described
elsewhere [43].
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